Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Receivables (2022 - 2025)

Historic Receivables for Fennec Pharmaceuticals (FENC) over the last 4 years, with Q3 2025 value amounting to $19.3 million.

  • Fennec Pharmaceuticals' Receivables rose 4985.28% to $19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year increase of 4985.28%. This contributed to the annual value of $12.9 million for FY2024, which is 4617.65% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Receivables is $19.3 million, which was up 4985.28% from $17.5 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Receivables peaked at $19.3 million during Q3 2025, and registered a low of $1.5 million during Q4 2022.
  • For the 4-year period, Fennec Pharmaceuticals' Receivables averaged around $10.0 million, with its median value being $11.3 million (2024).
  • In the last 5 years, Fennec Pharmaceuticals' Receivables soared by 51045.75% in 2024 and then skyrocketed by 4215.4% in 2025.
  • Fennec Pharmaceuticals' Receivables (Quarter) stood at $1.5 million in 2022, then skyrocketed by 470.49% to $8.8 million in 2023, then soared by 46.18% to $12.9 million in 2024, then soared by 50.13% to $19.3 million in 2025.
  • Its last three reported values are $19.3 million in Q3 2025, $17.5 million for Q2 2025, and $15.4 million during Q1 2025.